Palleon Pharmaceuticals

Palleon Pharmaceuticals

Palleon Pharmaceuticals

Palleon is targeting glycan-sensing checkpoints to unleash both the innate and adaptive immune responses to cancer.
Founded
2016
Raised
$148M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$100,000,000
Venture capital (Series B) - 2020
SR One Matrix Capital Management Takeda Ventures +5
Team Size
1–10
Employees
$100,000,000 Venture capital (Series B)
FinSMEs

Palleon Pharmaceuticals Raises $100M in Series B Funding

$48,000,000 Venture capital (Series A)
Xconomy

Palleon Lands $48M to Develop New Type of Checkpoint Cancer Drug

Health Science Funding